Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 5/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373939 | 1.00 | TSPO (0.49) | TSPOALBMAPK8 | |
| SCHEMBL12374026 | 0.94 | TSPO (0.52) | TSPOALBMAPK8 | |
| SCHEMBL12373943 | 0.94 | TSPO (0.52) | TSPOALBMAPK8 | |
| SCHEMBL12373914 | 0.93 | TSPO (0.48) | TSPO | |
| SCHEMBL1809104 | 0.93 | TSPO (0.48) | TSPO | |
| SCHEMBL12373937 | 0.93 | TSPO (0.58) | TSPOALBMAPK8 | |
| SCHEMBL12373989 | 0.93 | TSPO (0.58) | TSPOALBMAPK8 | |
| SCHEMBL12373921 | 0.92 | TSPO (0.47) | TSPOMAPK8 | |
| SCHEMBL12373972 | 0.92 | TSPO (0.47) | TSPOMAPK8 | |
| SCHEMBL12373940 | 0.92 | TSPO (0.57) | TSPOALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| WO-2010015340-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015387-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | GABRA6, GABRA4, GABRA1 | TSPO 33/4885ALB 1890/4885MAPK8 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.